150 related articles for article (PubMed ID: 38641755)
1. Comparison of the Measurement Properties of EQ-5D-5L and SF-6Dv2 in COVID-19 Patients in China.
Ding N; Zhou H; Chen C; Chen H; Shi Y
Appl Health Econ Health Policy; 2024 Jul; 22(4):555-568. PubMed ID: 38641755
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey.
Xie S; Wang D; Wu J; Liu C; Jiang W
Health Qual Life Outcomes; 2022 Jun; 20(1):96. PubMed ID: 35710429
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the measurement properties of the EQ-5D-5L and SF-6Dv2 among overweight and obesity populations in China.
Xie S; Li M; Wang D; Hong T; Guo W; Wu J
Health Qual Life Outcomes; 2023 Oct; 21(1):118. PubMed ID: 37904216
[TBL] [Abstract][Full Text] [Related]
4. Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population.
Xie S; Wu J; Chen G
Eur J Health Econ; 2024 Feb; 25(1):7-19. PubMed ID: 36709458
[TBL] [Abstract][Full Text] [Related]
5. Psychometric performance of EQ-5D-5L and SF-6DV2 in measuring health status of populations in Chinese university staff and students.
Zhou HJ; Zhang A; Wei J; Wu J; Luo N; Wang P
BMC Public Health; 2023 Nov; 23(1):2314. PubMed ID: 37993793
[TBL] [Abstract][Full Text] [Related]
6. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
[TBL] [Abstract][Full Text] [Related]
7. Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China.
Zhang A; Li J; Mao Z; Wang Z; Wu J; Luo N; Liu P; Wang P
Eur J Health Econ; 2024 Mar; ():. PubMed ID: 38451345
[TBL] [Abstract][Full Text] [Related]
8. Mapping IWQOL-Lite onto EQ-5D-5L and SF-6Dv2 among overweight and obese population in China.
Guo W; Xie S; Wang D; Wu J
Qual Life Res; 2024 Mar; 33(3):817-829. PubMed ID: 38167749
[TBL] [Abstract][Full Text] [Related]
9. Measurement properties of the EQ-5D-3L, EQ-5D-5L, and SF-6Dv2 in patients with late-onset Pompe disease.
Xu RH; Luo N; Dong D
Eur J Health Econ; 2024 Mar; ():. PubMed ID: 38472723
[TBL] [Abstract][Full Text] [Related]
10. Population Norms for SF-6Dv2 and EQ-5D-5L in China.
Xie S; Wu J; Xie F
Appl Health Econ Health Policy; 2022 Jul; 20(4):573-585. PubMed ID: 35132573
[TBL] [Abstract][Full Text] [Related]
11. A comparison of measurement properties between UK SF-6D and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population.
Kangwanrattanakul K
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):765-774. PubMed ID: 32981380
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia.
Xu RH; Dong D; Luo N; Wong EL; Wu Y; Yu S; Yang R; Liu J; Yuan H; Zhang S
Eur J Health Econ; 2021 Jun; 22(4):547-557. PubMed ID: 33761029
[TBL] [Abstract][Full Text] [Related]
13. Comparison of EQ-5D-5L, VAS, and SF-6D in Thai Patients on Peritoneal Dialysis.
Thaweethamcharoen T; Noparatayaporn P; Sritippayawan S; Aiyasanon N
Value Health Reg Issues; 2019 May; 18():59-64. PubMed ID: 30502661
[TBL] [Abstract][Full Text] [Related]
14. Health utility measurement for people living with HIV/AIDS under combined antiretroviral therapy: A comparison of EQ-5D-5L and SF-6D.
Wang X; Luo H; Yao E; Tang R; Dong W; Liu F; Liang J; Xiao M; Zhang Z; Niu J; Song L; Fu L; Li X; Qian S; Guo Q; Song Z
Medicine (Baltimore); 2022 Nov; 101(45):e31666. PubMed ID: 36397330
[TBL] [Abstract][Full Text] [Related]
15. Validity and responsiveness of EQ-5D-5L and SF-6D in patients with health complaints attributed to their amalgam fillings: a prospective cohort study of patients undergoing amalgam removal.
Lamu AN; Björkman L; Hamre HJ; Alræk T; Musial F; Robberstad B
Health Qual Life Outcomes; 2021 Apr; 19(1):125. PubMed ID: 33865400
[TBL] [Abstract][Full Text] [Related]
16. Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.
Selva-Sevilla C; Ferrara P; Gerónimo-Pardo M
Eur J Health Econ; 2020 Jun; 21(4):649-662. PubMed ID: 32065301
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of Chinese medicine quality of life assessment scale (CQ-11D) and EQ-5D-5L and SF-6D scales based on Chinese population.
Zhou J; Xu L; Pan J; Wang M; Zhou P; Wang W; Lu S; Zhu W
Qual Life Res; 2024 Jan; 33(1):113-122. PubMed ID: 37695478
[TBL] [Abstract][Full Text] [Related]
18. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
Cheung PWH; Wong CKH; Cheung JPY
Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
[TBL] [Abstract][Full Text] [Related]
19. EQ-5D-5L and SF-6Dv2 utility scores in people living with chronic low back pain: a survey from Quebec.
Poder TG; Wang L; Carrier N
BMJ Open; 2020 Sep; 10(9):e035722. PubMed ID: 32933957
[TBL] [Abstract][Full Text] [Related]
20. A Head-to-Head Comparison of UK SF-6D and Thai and UK EQ-5D-5L Value Sets in Thai Patients with Chronic Diseases.
Sakthong P; Munpan W
Appl Health Econ Health Policy; 2017 Oct; 15(5):669-679. PubMed ID: 28290106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
